Inhibikase Therapeutics, Inc. (IKT)
| Market Cap | 480.74M +273.5% |
| Revenue (ttm) | n/a |
| Net Income | -50.96M |
| EPS | -0.43 |
| Shares Out | 195.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 479,215 |
| Open | 2.440 |
| Previous Close | 2.470 |
| Day's Range | 2.420 - 2.525 |
| 52-Week Range | 1.330 - 2.530 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+143.9%) |
| Earnings Date | Aug 11, 2026 |
About IKT
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for IKT stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 143.90% from the latest price.
News
Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA
Inhibikase Therapeutics (IKT) announced that the FDA has granted Orphan Drug Designation to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH. Published firs...
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Ar...
Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation
Inhibikase Therapeutics (IKT)’ treatment of pulmonary arterial hypertension was granted FDA orphan designation, according to a post on the agency’s website.
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Ar...
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to pur...
Inhibikase Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Inhibikase Therapeutics (IKT) with an Outperform rating and $5 price target Inhibikase is developing IKT-001, an oral prodrug of imatinib designed to preserve imatini...
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Art...
Inhibikase Therapeutics Earnings release: Q1 2026
Inhibikase Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Inhibikase Therapeutics Quarterly report: Q1 2026
Inhibikase Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Inhibikase Therapeutics Proxy statement: Proxy filing
Inhibikase Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Inhibikase Therapeutics Proxy statement: Proxy filing
Inhibikase Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Inhibikase Therapeutics Proxy statement: Proxy filing
Inhibikase Therapeutics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
Inhibikase Therapeutics (IKT) announced that the first patient has been enrolled in the company’s pivotal Phase 3 study IMPROVE-PAH study.
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary A...
Inhibikase Therapeutics Slides: Corporate presentation
Inhibikase Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify ...
Inhibikase Therapeutics Annual report: Q4 2025
Inhibikase Therapeutics has published its Q4 2025 annual report on March 26, 2026.
Inhibikase Therapeutics Earnings release: Q4 2025
Inhibikase Therapeutics released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Inhibikase Therapeutics initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Inhibikase Therapeutics (IKT) with a Buy rating and $4 price target The firm views Inhibikase’s TKI imatinib approach in pulmonary arterial hypertension as “de-risked.”...
Inhibikase Therapeutics initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Inhibikase Therapeutics (IKT) with a Buy rating and $4 price target
Inhibikase Therapeutics initiated with a Buy at BofA
BofA initiated coverage of Inhibikase Therapeutics (IKT) with a Buy rating and $6 price target Investors “seemed largely unfazed” by FDA’s decision last November to forego a phase 2 in…
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer initiated coverage of Inhibikase Therapeutics (IKT) with an Overweight rating and $4 price target Inhibikase is now essentially defined by IKT-001, its oral ima...
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
The deal priced below last closing price of $1.53. Jefferies, BofA and Cantor Fitzgerald are acting as joint book running managers for the offering.
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify t...
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
Jefferies, BofA and Cantor Fitzgerald are acting as joint book running managers for the offering.